Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Human graft endothelial cells (ECs) can act as antigen-presenting cells to initiate allograft rejection by host memory T cells. Rapamycin, an mTOR inhibitor used clinically to suppress T cell responses, also acts on DCs, rendering them tolerogenic. Here, we report the effects of rapamycin on EC alloimmunogenicity. Compared with mock-treated cells, rapamycin-pretreated human ECs (rapa-ECs) stimulated less proliferation and cytokine secretion from allogeneic CD4+ memory cells, an effect mimicked by shRNA knockdown of mTOR or raptor in ECs. The effects of rapamycin persisted for several days and were linked to upregulation of the inhibitory molecules PD-L1 and PD-L2 on rapa-ECs. Additionally, rapa-ECs produced lower levels of the inflammatory cytokine IL-6. CD4+ memory cells activated by allogeneic rapa-ECs became hyporesponsive to restimulation in an alloantigen-specific manner and contained higher percentages of suppressive CD4+CD25(hi)CD127(lo)FoxP3+ cells that did not produce effector cytokines. In a human-mouse chimeric model of allograft rejection, rapamycin pretreatment of human arterial allografts increased graft EC expression of PD-L1 and PD-L2 and reduced subsequent infiltration of allogeneic effector T cells into the artery intima and intimal expansion. Preoperative conditioning of allograft ECs with rapamycin could potentially reduce immune-mediated rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“In the cell, mTOR exists in two distinct signaling complexes, known as mTORC1 and mTORC2, which have differing upstream inputs and downstream outputs (77).”
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 4×
“Among these subsets are Th1 cells, which express the master transcription factor T-bet and secrete IFN-γ ; Th2 cells, which express the master transcription factor GATA3 and secrete IL-4, IL-5, and IL-13; and Th17 cells, which express the master transcription factor ROR γ T and secrete IL-17A and IL-17F (20, 21).”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“However, we caution that such an intervention requires additional preclinical study, as rapamycin has also been reported to have proinflammatory effects on monocytes, DCs, and CD8 + T cells (75, 76).”
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011 · cited 1×
“In humans, FoxP3 is not an exclusive marker of Tregs, as it is also transiently expressed on activated conventional CD4 + T cells (48, 49).”
Allan, S. E., Crome, S. Q., Crellin, N. K., Passerini, L., Steiner, T. S., Bacchetta, R., Roncarolo, M. G., & Levings, M. K. (2007) · International Immunology · doi:10.1093/intimm/dxm014 · Cited by 872 · cited 1×
“In humans, FoxP3 is not an exclusive marker of Tregs, as it is also transiently expressed on activated conventional CD4 + T cells (48, 49).”
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · cited 8×
“In other words, human ECs are the only functional allogeneic APCs in the graft.”
InfluentialThe TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801 · cited 1×
“However, we caution that such an intervention requires additional preclinical study, as rapamycin has also been reported to have proinflammatory effects on monocytes, DCs, and CD8 + T cells (75, 76).”
Afzali, B., Lombardi, G., Lechler, R. I., & Lord, G. M. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03356.x · Cited by 762
Heterologous immunity provides a potent barrier to transplantation tolerance
Adams, A. B., Williams, M. A., Jones, T. R., Shirasugi, N., Durham, M. M., Kaech, S. M., Wherry, E. J., Onami, T., Lanier, J. G., Kokko, K. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317477 · Cited by 616 · cited 1×
“Memory T cells are important mediators of rejection in clinical transplantation (14, 15), and a significant percentage of circulating memory cells in human transplant recipients, likely generated during prior microbial infections, cross-react to recognize donor graft alloantigens (16).”
B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5928 · Cited by 208 · cited 1×
“In allogeneic heart (62), corneal (63), and skin (64) transplant models, blockade or absence of PD-1 signaling accelerated rejection, while administration of PD-L1.”
Cited by
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Xie, L., Sun, F., Wang, J., Mao, X., Xie, L., Yang, S.-H., Su, D.-M., Simpkins, J. W., Greenberg, D. A., & Jin, K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303492 · Cited by 175
“It has been reported that rapamycin-treated endothelial cells and dendritic cells may promote Treg activity in ischemic brains (63, 64).”
BackgroundAntigen Presentation by Vascular Cells
Pober, J. S., Merola, J., Liu, R., & Manes, T. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01907 · Cited by 165
Self-citation
Metadata
- Authors
- Wang, C., Yi, T., Qin, L., Maldonado, R. A., von Andrian, U. H., Kulkarni, S., Tellides, G., & Pober, J. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-08
- Volume
- 123
- Issue
- 4
- Pages
- 1677-1693
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2108923719
- Cited by
- 73
- References
- 11
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. https://app.cochat.ai/papers/10.1172/jci66204
- The paper
- Wang, C., Yi, T., Qin, L., Maldonado, R. A., von Andrian, U. H., Kulkarni, S., Tellides, G., & Pober, J. S. (2013). Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci66204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.